• Je něco špatně v tomto záznamu ?

Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

F. Baron, M. Labopin, J. Versluis, J. Vydra, PA. von dem Borne, E. Nicholson, D. Blaise, R. Protheroe, A. Kulagin, CE. Bulabois, M. Rovira, P. Chevallier, E. Forcade, J. Byrne, J. Sanz, A. Ruggeri, M. Mohty, F. Ciceri

. 2024 ; 99 (12) : 2296-2305. [pub] 20240831

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25003287

Grantová podpora
Fonds De La Recherche Scientifique - FNRS

The best donor option for acute myeloid leukemia (AML) patients lacking an HLA-matched donor has remained intensively debated. We herein report the results of a large retrospective registry study comparing hematopoietic cell transplantation (HCT) outcomes between double-unit umbilical cord blood transplantation (dCBT, n = 209) versus 9/10 HLA-matched unrelated donor (UD) with posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis (UD 9/10, n = 270) in patients with AML in first complete remission (CR1). Inclusion criteria consisted of adult patient, AML in CR1 at transplantation, either peripheral blood stem cells (PBSC) from UD 9/10 with PTCy as GVHD prophylaxis or dCBT without PTCy, transplantation between 2013 and 2021, and no in vivo T-cell depletion. The 180-day cumulative incidence of grade II-IV acute GVHD was 29% in UD 9/10 versus 44% in dCBT recipients (p = .001). After adjustment for covariates, dCBT recipients had a higher non-relapse mortality (HR = 2.35, 95% CI: 1.23-4.48; p = .01), comparable relapse incidence (HR = 1.12, 95% CI: 0.67-1.86; p = .66), lower leukemia-free survival (HR = 1.5, 95% CI: 1.01-2.23; p = .047), and lower overall survival (HR = 1.66, 95% CI: 1.08-2.55; p = .02) compared with patients receiving UD 9/10 HCT. In summary, our results suggest that transplantation outcomes are better with UD 9/10 with PTCy-based GVHD prophylaxis than with dCBT for AML patients in CR1. These data might support the use of UD 9/10 with PTCy-based GVHD prophylaxis over dCBT in AML patients lacking an HLA-matched donor.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003287
003      
CZ-PrNML
005      
20250206104227.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ajh.27466 $2 doi
035    __
$a (PubMed)39215605
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Baron, Frédéric $u Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Liege, Belgium $1 https://orcid.org/0000000229443812
245    10
$a Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide-based graft-versus-host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation / $c F. Baron, M. Labopin, J. Versluis, J. Vydra, PA. von dem Borne, E. Nicholson, D. Blaise, R. Protheroe, A. Kulagin, CE. Bulabois, M. Rovira, P. Chevallier, E. Forcade, J. Byrne, J. Sanz, A. Ruggeri, M. Mohty, F. Ciceri
520    9_
$a The best donor option for acute myeloid leukemia (AML) patients lacking an HLA-matched donor has remained intensively debated. We herein report the results of a large retrospective registry study comparing hematopoietic cell transplantation (HCT) outcomes between double-unit umbilical cord blood transplantation (dCBT, n = 209) versus 9/10 HLA-matched unrelated donor (UD) with posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis (UD 9/10, n = 270) in patients with AML in first complete remission (CR1). Inclusion criteria consisted of adult patient, AML in CR1 at transplantation, either peripheral blood stem cells (PBSC) from UD 9/10 with PTCy as GVHD prophylaxis or dCBT without PTCy, transplantation between 2013 and 2021, and no in vivo T-cell depletion. The 180-day cumulative incidence of grade II-IV acute GVHD was 29% in UD 9/10 versus 44% in dCBT recipients (p = .001). After adjustment for covariates, dCBT recipients had a higher non-relapse mortality (HR = 2.35, 95% CI: 1.23-4.48; p = .01), comparable relapse incidence (HR = 1.12, 95% CI: 0.67-1.86; p = .66), lower leukemia-free survival (HR = 1.5, 95% CI: 1.01-2.23; p = .047), and lower overall survival (HR = 1.66, 95% CI: 1.08-2.55; p = .02) compared with patients receiving UD 9/10 HCT. In summary, our results suggest that transplantation outcomes are better with UD 9/10 with PTCy-based GVHD prophylaxis than with dCBT for AML patients in CR1. These data might support the use of UD 9/10 with PTCy-based GVHD prophylaxis over dCBT in AML patients lacking an HLA-matched donor.
650    _2
$a lidé $7 D006801
650    12
$a nemoc štěpu proti hostiteli $x prevence a kontrola $x etiologie $x mortalita $7 D006086
650    12
$a akutní myeloidní leukemie $x terapie $x mortalita $7 D015470
650    12
$a cyklofosfamid $x terapeutické užití $x aplikace a dávkování $7 D003520
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dospělí $7 D000328
650    12
$a nepříbuzný dárce $7 D061349
650    12
$a transplantace kmenových buněk z pupečníkové krve $7 D036101
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a senioři $7 D000368
650    _2
$a indukce remise $7 D012074
650    _2
$a mladiství $7 D000293
650    _2
$a mladý dospělý $7 D055815
650    _2
$a registrace $7 D012042
650    _2
$a transplantace hematopoetických kmenových buněk $7 D018380
655    _2
$a časopisecké články $7 D016428
700    1_
$a Labopin, Myriam $u EBMT Paris Study Unit, Paris, France $u Clinical Hematology and Cellular Therapy Department, Saint Antoine Hospital, Paris, France $u INSERM UMRs 938, Paris, France $u Sorbonne University, Paris, France
700    1_
$a Versluis, Jurjen $u Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a von dem Borne, Peter A $u Leiden University Medical Center, Leiden, The Netherlands
700    1_
$a Nicholson, Emma $u Royal Marsden Hospital, London, UK $1 https://orcid.org/0000000264390795
700    1_
$a Blaise, Didier $u Programme de transplantation et d'immunothérapie cellulaire, département d'hématologie, Institut Paoli Calmettes, Laboratoire management sport cancer, Aix Marseille université, Marseille, France
700    1_
$a Protheroe, Rachel $u University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
700    1_
$a Kulagin, Alexander $u RM Gorbacheva Research Institute, Pavlov University, Saint Petersburg, Russian Federation $1 https://orcid.org/0000000295894136
700    1_
$a Bulabois, Claude Eric $u CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble, France
700    1_
$a Rovira, Montserrat $u Hospital Clinic, Barcelona, Spain
700    1_
$a Chevallier, Patrice $u CHU Nantes, Nantes, France $1 https://orcid.org/0000000331425581
700    1_
$a Forcade, Edouard $u Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France
700    1_
$a Byrne, Jenny $u Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK
700    1_
$a Sanz, Jaime $u Hematology Department, University Hospital La Fe, Valencia, Spain
700    1_
$a Ruggeri, Annalisa $u IRCCS Ospedale San Raffaele s.r.l., Haematology and BMT, Milan, Italy $1 https://orcid.org/0000000272612765
700    1_
$a Mohty, Mohamad $u Clinical Hematology and Cellular Therapy Department, Saint Antoine Hospital, Paris, France $u INSERM UMRs 938, Paris, France $u Sorbonne University, Paris, France
700    1_
$a Ciceri, Fabio $u IRCCS Ospedale San Raffaele s.r.l., Haematology and BMT, Milan, Italy $u Vita-Salute San Raffaele University, Milano, Italy
773    0_
$w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 99, č. 12 (2024), s. 2296-2305
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39215605 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104222 $b ABA008
999    __
$a ok $b bmc $g 2263190 $s 1239294
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 99 $c 12 $d 2296-2305 $e 20240831 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
GRA    __
$p Fonds De La Recherche Scientifique - FNRS
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace